Why is inflammation elevated in treated HIV infection and why does it matter? Steven G. Deeks Professor of Medicine University of California, San Francisco.

Slides:



Advertisements
Similar presentations
Metabolic consequences of HIV-induced inflammation Jacqueline Capeau INSERM U938, Université Pierre et Marie Curie Faculté de Médecine, site Saint-Antoine,
Advertisements

Impact of Tryptophan Catabolism on CD4+ T Cell Recovery and Mortality in HIV-infected Ugandans Initiating ART Peter W. Hunt, Sheri Weiser, Yong Huang,
Immune-Based Interventions for HIV Infection and AIDS Alan Landay, PhD Professor and Chairman Department of Immunology/Microbiology Rush University Medical.
HCV cure: new treatment paradigms for HCV infection Sanjay Bhagani Consultant Physician/Senior Lecturer Royal Free Hospital/UCL London.
Interventions to Reduce Inflammation and Immune Activation in Treated HIV Infection Peter W. Hunt, MD Assistant Professor of Medicine UCSF HIV/AIDS Division.
Immuno-virological discordance in treated suppressed patients Julià Blanco IGTP/IrsiCaixa Badalona, Catalonia, Spain.
HLA-B57 does not fully explain the ability of HIV controllers to clear HCV infection Alice K. Asher 1, RN, MS; Glenn-Milo Santos 1, MPH; Jennifer Evans,
Should we treat HIV Controllers ? IAS 2013 Pr Olivier Lambotte Department of internal medicine and clinical immunology Bicêtre Hospital, University Paris.
Offering ARV Treatment to All HIV-infected Persons in San Francisco Grant Colfax, MD Director of HIV Prevention and Research San Francisco Department of.
The role of HIV infection and Co-infections in Serious Non-AIDS Events Peter W. Hunt, M.D Associate Professor of Medicine, UCSF.
The pathogenesis of persistent HIV-associated inflammation during long-term antiretroviral therapy Steven G. Deeks Professor of Medicine University of.
Slide 1 of 11 From CB Hicks, MD, at Chicago, IL: May 20, 2013, IAS-USA. IAS–USA Charles B. Hicks, MD Professor of Medicine Duke University Medical Center.
Chronic diseases in HIV Francois Venter Wits Reproductive Health & HIV Institute
Aging with HIV infection Bill Powderly MD School of Medicine and Medical Sciences University College Dublin Ireland.
Impact of Active Tuberculosis on Immune Recovery in HIV-infected Individuals Receiving ART H.Y. Tan 1, Y.K. Yong 1, L.Y. Ong 1, Y.M. Lee 1, S.F.S. Omar.
Cardiovascular Complications of HIV Mark Boyd MD, FRACP The Kirby Institute for infection and immunity in society 7 th IAS Conference Kuala Lumpur, Malaysia.
Protective HLA Class I alleles are associated with reduced immune activation in Primary HIV infection Elizabeth Hamlyn 1, Stephen Hickling 2, Abdel Babiker.
Immune Reconstitution Inflammatory Syndrome (IRIS)
Role of Antiretroviral Therapy, Viral Replication, and HIV Infection in Atherosclerosis Priscilla Y. Hsue, Peter W. Hunt, Jeffrey N. Martin, Amanda Schnell,
2014 “Towards an HIV Cure” symposium Melbourne The Immune Checkpoints PD-1, LAG-3 and TIGIT are Biomarkers of HIV Infected Cells During ART and Identify.
Slide 1 of 24 From DC Douek, MD, at San Francisco, CA: March 24, 2013, IAS-USA. IAS–USA Daniel C. Douek, MD, PhD Bethesda, Maryland Immune Activation,
Cardiovascular Disease: Predicting Risk and Monitoring Outcomes Monica R. Shah, MD, FACC NHLBI AIDS Coordinator Conference on Retroviruses and Opportunistic.
Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity Peter W. Hunt, MD Associate Professor of Medicine UCSF HIV/AIDS Division.
Cryptococcal IRIS: Pathogenesis & Pearls for Clinical Management
Long Term Management of HIV Infection in Aging Adults: Current Challenges, Future Strategies Andrew Zolopa, MD Stanford University.
Cell- and Tissue-based Measures of Viral Persistence Are Associated with Immune Activation and PD-1-Expressing CD4+ T cells H Hatano 1, V Jain 1, PW Hunt.
Toronto I-II 4:00 pm The end of AIDS: HIV as a chronic inflammatory disease Steven Deeks Professor of medicine in residence at the University of California,
Risk factors of Heart disease Dr. Mahmoudian.. Risk factors for coronary artery atherosclerosis Hyperlipidemia and dyslipidemia Hypertension Cigarette.
Factors associated with IL-6 levels during HIV infection Álvaro Borges, Jemma O’Connor, Andrew Phillips, Frederikke Rönsholt, Sarah Pett, Michael Vjecha,
Risk of serious disease and death in people with HIV viral suppression on ART: an epidemiologic perspective The Lancet and Cell Meeting What Will it Take.
Slide 1 of 10 From DC Douek, MD, at Atlanta, GA: April 10, 2013, IAS-USA. IAS–USA Daniel C. Douek, MD, PhD Bethesda, Maryland Immune Activation, HIV Persistence,
Washington D.C., USA, July 2012www.aids2012.org Track A – BASIC SCIENCE Rapporteur Session Jacques Fellay EPFL, Lausanne, Switzerland.
AfterBefore PTH pg/ml PTH pg/ml AfterBefore Case Report 1) Age 53, 17 yrs HIV infection TDF/FTC/EFZ Baseline 25(OH)D.
HIV Pathogenesis Update 2010: Immune Activation & Inflammation Richard Jefferys Coordinator, Michael Palm Basic Science, Vaccines & Prevention Project,
Slide 1 of 11 From DA Wohl, MD, at New York, NY: May 03, 2012, IAS-USA. IAS–USA David Alain Wohl, MD Associate Professor of Medicine The University of.
Diastolic Dysfunction is Common in Asymptomatic HIV Patients Priscilla Y. Hsue 1,2, Husam H. Farah 1,2, Ann F. Bolger 1,2, Swapna Palav 2, Samira Ahmed.
Slide 1 of 25 From VG Valcour, MD, at Washington, DC: June 18, 2013, IAS-USA. IAS–USA Victor G. Valcour, MD Professor of Geriatric Medicine University.
HIV and serious non-AIDS conditions Five Years after the SMART Study, a Paradigm Shifting Trial INSIGHT Symposium XIX International AIDS Conference Washington.
Cenicriviroc: A Potent Dual Chemokine Receptor Antagonist (CCR5/CCR2) in Phase 2b Development with Potential to Transform HIV Therapy Cenicriviroc: A Potent.
The Interplay of the Osteoprotegerin/RANKL Axis and Dysfunctional HDL in HIV-Infected Adults AIDS Clinical Trials Group Study NWCS 332/A5078 Kelesidis.
T-Cell Senescence & Inflammation HIV Research Catalyst Forum, April
Anti-HIV Antibody Responses Reflect the Quantifiable HIV Reservoir Size Sulggi Lee, M.D., Ph.D. Assistant Professor of Medicine University of California,
Peter W. Hunt, MD Associate Professor of Medicine in Residence
I. Jean Davis, PhD, PA, AAHIVS Manager - Clinical Services Desert AIDS Project.
HIV Infection and Accelerated Aging Why is this happening? What can be done to prevent or reverse the process? Steven G. Deeks, MD Professor of Medicine.
Primary HIV-1 Infection Pathogenesis, Diagnosis, and Treatment Summary of Evidence Martin Markowitz M.D. Clinical Director and Staff Investigator Aaron.
The role of treatment versus disease in causing premature non-AIDS morbidity Judith S. Currier, MD University of California, Los Angeles.
Biological Relationship Between HIV and Nutrition Christine Wanke, MD AIDS Turning the Tide Together.
Evidence for the link between markers of inflammation, coagulation and immune activation and end organ disease Session: Immune Activation/Inflammation.
HIV infection and cardiovascular diseases Matthew S. Freiberg, MD, MSc University of Pittsburgh School of Medicine and Graduate School of Public Health.
Clinic-based Translational Research Cohort/ Clinical Trial Immunology Core Lab (Sinclair) Basic Immunology Lab (McCune) Virology Core Lab (Liegler) Basic.
Immune activation & Inflammation in HIV infection
Can early antiretroviral therapy fully restore health? Workshop on Pathogeneses and Management of Long-Term Complications of ART IAS Conference, Rome July.
Slide 1 of 44 From SG Weibel, MD, at San Francisco, CA: May 6, 2016, IAS-USA. Getting Hotter As We Get Older Sara Gianella Weibel, MD Assistant Professor.
E. Turner Overton, MD Associate Professor of Medicine University of Alabama at Birmingham Birmingham, Alabama Statins, Rainwater, and Pure Grain Alcohol:
Diego Ripamonti - Malattie Infettive - Bergamo Simposio HOT TOPICS Hot topics in HIV 2015.
Slideset on: Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving.
The FAVORIT Study (Folic Acid for Vascular Outcome Reduction in Transplantation) Source Bostom AG, Carpenter MA, Kusek JW, et al. Homocysteine-lowering.
Pathophysiology of Non-Communicable Diseases in Treated HIV Infection: Is there a common path? Peter W. Hunt, MD Associate Professor of Medicine Division.
Immune Ageing and Viral Co-Factors
State of HIV Cure Research
Inflammation Markers and The Risk of Non-AIDS Events
HIV and Inflammation Jihad Slim, MD June 2016.
Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load by Steven G. Deeks, Christina.
The Impact of Aging on People Living with HIV
Steven G. Deeks, Russell Tracy, Daniel C. Douek  Immunity 
Residual Disease and Immune Activation/Inflammation on ART
Human Immunodeficiency Virus Controllers: Mechanisms of Durable Virus Control in the Absence of Antiretroviral Therapy  Steven G. Deeks, Bruce D. Walker 
Volume 141, Issue 4, Pages e3 (October 2011)
Steven G. Deeks, Russell Tracy, Daniel C. Douek  Immunity 
Presentation transcript:

Why is inflammation elevated in treated HIV infection and why does it matter? Steven G. Deeks Professor of Medicine University of California, San Francisco

Many Age-associated Diseases Are More Common in Treated HIV Disease Than In Age- matched Uninfected Persons Cardiovascular disease Cancer (non-AIDS) Bone fractures/osteopenia Left ventricular dysfunction Liver failure Kidney failure Cognitive decline Frailty Immune system Multiple factors likely explain this increased risk, including co- morbid conditions and antiretroviral drug toxicity

Schouten J AIDS 2012 Co-morbid conditions common in HIV-infected adults HIV-infected adults age similar to uninfected adults > 65

Inflammatory Biomarkers Predict Risk for All-Cause Mortality among Treated Adults CohortDesignT cell acti- vation CRPIL-6K/T IDO Cysta- atin C sCD- 14 D- dimer Fibrin- ogen Hyalu- ronic Acid SMART ESPRIT Case- control ✔✔✔✔✔ FRAM Cohort ✔✔✔ SOCA/ SCOPE Cohort ✔✔✔✔✔✔ UARTO Cohort ✔✔ VACS Cohort ✔✔ FIRST (Pre-ART) Case- control ✔✔✔✔ Pfidisas (Pre-ART) Case- control ✔✔✔ T cells Innate Microbes Coagulation Fibrosis

“Over the past decade, it has become widely accepted that inflammation is a driving force behind chronic diseases that will kill nearly all of us... ” Science, 2010 Chronic inflammation is also harmful in non-HIV-infected adults Courtesy of Peter Reiss

Is there something unique about inflammation in HIV disease?

T cell “activation” is lower in treated than untreated adults, but consistently higher than “normal” Hunt et al JID 2003, PLoS ONE 2011 and unpublished HIV – (n=132) HIV + ART (n=65) HIV + Untreated (n=82)

% Diff. from General Population (MESA) Neuhaus et al JID 2010 Among those with undetectable viral load (<400 copies/mL), hsCRP was 40% higher, IL- 6 was 60% higher, and D-dimer was 49% higher, compared with controls from MESA Many common plasma biomarkers of inflammation are also higher in treated HIV disease than “normal”

Among treated adults, D-dimers (and perhaps other biomarkers) are stable over years Courtesy of Jens Lundgren

Effect on inflammation in predicting mortality higher in HIV disease than the general population (SOCA/SCOPE) Hunt et al CROI 12

A single measurement of D-dimers predicts mortality through 8 years of observation, whereas effect wanes in 2-3 years in general population (SMART/ESPRIT; n=3227) There were only 5 deaths over 8 years among those in the lowest quartile (as compared to 45 deaths in highest quartile) Lane et al; CROI 2011

Are all of the biomarkers describing the same mechanistic pathway?

Biomarkers covering apparently unique pathways (inflammation and coagulation) provided independent prognostic capacity in FRAM Associations for CRP and Fibrinogen persist when CD4 >500 Tien et. al. JAIDS 2010;55(3):

Among adults with durable viral suppression, a low CD4+ T cell count is associated with significant T cell abnormalities Hatano CROI 2011 P = P < P = 0.05

After controlling for CD4+ T cell count, inflammatory biomarkers have stronger prognostic effect that T cell activationtreated infection Hunt et al CROI 12

Early ART Also Appears to Reduce Residual T Cell Activation during ART Jain et al, CROI 2011

What causes HIV- associated inflammation?

Inflammation ↑ Endothelium adhesion ↑ Monocyte activation Dyslipidemia Hypercoagulation/ thrombotic events Endothelial dysfunction Inflammation ↑ Endothelium adhesion ↑ Monocyte activation Dyslipidemia Hypercoagulation/ thrombotic events Endothelial dysfunction Microbial translocation HIV-associated fat Metabolic syndrome HIV production HIV replication CMV Excess pathogens HIV-mediated loss of regulatory cells (Tregs)

Conclusions Inflammation during treated HIV disease is unique Higher than expected Stable over time Stronger prognostic significance Multiple mechanisms cause activation Residual HIV production (or replication) Microbial translocation CMV and other co-pathogens Loss of immunoregulatory responses Lymphoid fibrosis Metabolic syndrome, abdominal obesity Treatment toxicity (e.g., telomerase inhibition)

Acknowledgements UCSF Peter Hunt Hiroyu Hatano Priscilla Hsue Jeff Martin Becky Hoh Ma Somsouk Vivek Jain Elizabeth Sinclair Mike Busch Steve Yukl Joe Wong Mike McCune INSIGHT Jason Baker Cliff Lane Andrew Phillips Jim Neaton Jens Lundgren Elsewhere Netanya Sandler Danny Douek Mike Lederman (CLIC) Peter Reiss Rafick Sekaly Tim Schacker